Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.35 |
| ▸ | CD38 | P28907 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25192045 | 1.00 | HPGDS (0.41) | HPGDSFGFR1DDR2MCL1RIPK2 | |
| SCHEMBL30336044 | 0.79 | KDM5B (0.42) | FGFR1DDR2MCL1ALDH1A1KDM5B | |
| SCHEMBL25183152 | 0.79 | KDM5B (0.42) | FGFR1DDR2MCL1ALDH1A1KDM5B | |
| SCHEMBL25264715 | 0.75 | HPGDS (0.47) | HPGDSCD38RBP4TTR | |
| SCHEMBL25188305 | 0.75 | HPGDS (0.47) | HPGDSCD38RBP4TTR | |
| SCHEMBL25207007 | 0.73 | HPGDS (0.45) | HPGDSCD38RBP4TTR | |
| SCHEMBL25207009 | 0.73 | HPGDS (0.45) | HPGDSCD38RBP4TTR | |
| SCHEMBL25265027 | 0.72 | CD38 (0.48) | HPGDSCD38RBP4TTR | |
| SCHEMBL25192979 | 0.72 | CD38 (0.48) | HPGDSCD38RBP4TTR | |
| SCHEMBL25264766 | 0.68 | RBP4 (0.44) | HPGDSCD38SPRRBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | Cerevance, Inc. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4430034-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | Cerevance, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | CD38, CXCR4, P2RY1 | HPGDS 213/4885FGFR1 1375/4885DDR2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.